Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 13/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.54 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.54 |
| ▸ | ACHE | P22303 | 1/20 | 0.52 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1911982 | 0.93 | LTA4H (0.55) | HRH3POLBKDM4E | |
| SCHEMBL10207620 | 0.92 | LTA4H (0.56) | POLBMAPTKDM4EALDH1A1KMT2A | |
| SCHEMBL1706927 | 0.89 | HRH3 (0.58) | HRH3KCNH2POLBMAPTKDM4E | |
| SCHEMBL21814294 | 0.88 | HRH3 (0.56) | HRH3KCNH2POLBMAPTKDM4E | |
| SCHEMBL1622564 | 0.84 | HRH3 (0.64) | HRH3KCNH2KDM4EL3MBTL1ACHE | |
| SCHEMBL2890075 | 0.83 | HRH3 (0.61) | HRH3KCNH2KDM4EL3MBTL1KMT2A | |
| SCHEMBL1962645 | 0.82 | LTA4H (0.58) | HRH3KCNH2POLBKDM4E | |
| SCHEMBL14419428 | 0.82 | KDM4E (0.59) | HRH3KCNH2KDM4EL3MBTL1ALDH1A1 | |
| SCHEMBL1776035 | 0.81 | HRH3 (0.62) | HRH3KCNH2POLBMAPTKDM4E | |
| SCHEMBL1964263 | 0.81 | LTA4H (0.59) | HRH3POLBKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
| EP-2440534-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | Cellzome Limited (GB) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010142766-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010142766-A2 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | CELLZOME LIMITED (GB) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142667-A1 | PYRIMIDINE DERIVATIVES AS ZAP-70 INHIBITORS | ZAP70, LCK, DPY30 | HRH3 310/4885KCNH2 1942/4885POLB 741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.